Frank Seebach
Regeneron (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Nonmelanoma Skin Cancer Studies, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,359 cited
- → Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial(2021)783 cited
- → Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma(2022)292 cited
- → Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial(2022)279 cited
- → Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial(2021)268 cited
- → Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial(2023)91 cited
- → Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study(2023)91 cited
- → First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial(2023)87 cited
- → Endogenous Heparin-Like Substances Significantly Impair Coagulation in Patients Undergoing Orthotopic Liver Transplantation(1998)83 cited
- → Functional Activation of Heat Shock Factor and Hypoxia-Inducible Factor in the Kidney(2002)68 cited